07 Jan 2001

Duspatalin 135 - España

Updated: 07 Jan 2001

Duspatalin 135 mg 60 grageas

- Síndrome del colon irritable primario y otras patologías relacionadas: colon irritable crónico, estreñimiento espástico, colitis mucosa, colitis espástica. La mebeverina se utiliza para tratar los síntomas de dolor, calambres abdominales persistentes, diarrea no específica (con o sin estreñimiento alternante) y sensación de plenitud. - Espasmos gastrointestinales secundarios a enfermedades orgánicas: diverticulosis y diverticulitis. - Enteriris.

Duspatalin 135 Description, Presentation and Dosage

Duspatalin 135 Description

Duspatalin 135 Drug Class Description

Antiespasmodicos no anticolinergicos

Duspatalin 135 Drug Description

GRAGEAS

Duspatalin 135 Presentation

Duspatalin 135 Presentation

Vía oral: 135 mg/8 h, 20 min antes de las comidas. A menudo es necesario un mes o más de tratamiento.

Duspatalin 135 Manufacturer

SOLVAY PHARMA

Related Learning Zones

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The Cystic Fibrosis Knowledge Centre provides healthcare professionals with access to disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

Obesity CME series

Obesity CME series

This European Obesity Initiative CME series contains three online modules, which are ideal for healthcare professionals looking to widen their understanding of obesity as a serious medical illness. Each module is EACCME-accredited and free to complete. Successful completion of the series will earn participants a combined total of 5 European CME credits (ECMECs).

Duspatalin 135 Dosage

Duspatalin 135 Child Dosage

No se dispone de suficiente experiencia clínica en este grupo de edad. Uso no recomendado.

Duspatalin 135 Elderly Dosage

No se han descrito problemas específicos en pacientes geriátricos.

Duspatalin 135 Precautions, Reactions and Contraindications

Duspatalin 135 Special Precautions

Duspatalin 135 Adverse Reactions

Duspatalin 135 Adverse Reactions

Los efectos adversos de mebeverina son, en general, leves y transitorios. Las reacciones adversas más características son: -Excepcionalmente (<<1%): mareos, cefalea, taquicardia, alteraciones del sueño, urticaria, erupciones exantemáticas.

Related Drugs - Gastroenterologia

Back to top